SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doc Bones who wrote (1755)8/13/2003 11:24:20 AM
From: VIXandMore   of 1762
 
IDEC Pharma upped to Outperform at RBC (IDPH) 33.10
The upgrade from Sector Perform is based on view that Biogen IDEC is a compelling investment opportunity on valuation. Firm recommends using IDPH shares as a vehicle into the entity. Price target goes to $52 from $40, which is based on 32x firm's 2004 pro forma est and a PEG of 1.5x. (from Briefing.com)

The stock surged briefly, but then gave back the gains from this rare piece of good news
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News